Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Burosumab

EU orphan designation number: EU/3/18/2011   
Active ingredient: Burosumab
Indication: Treatment of phosphaturic mesenchymal tumour
Sponsor: Kyowa Kirin Holdings B.V.
Bloemlaan 2, 2132 NP Hoofddorp, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/04/2018 Orphan designation EMA/OD/026/17 (2018)2407 of 16/04/2018
14/02/2019 Transfer of orphan designation EMA/OD/0000003746 (2019)1344 of 12/02/2019